Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness

References

• Wu JJ, Feldman SR, Koo J, et al. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):1–9.
   Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther. 2021;11(3):1053–1064.
   Web of Science ®Google Scholar
• Körber A, Wilsmann-Theis D, Augustin M, et al. Topische Therapie bei Psoriasis vulgaris – ein Behandlungspfad [Topical therapy for psoriasis vulgaris. A treatment pathway]. J Dtsch Dermatol Ges. 2019;17(S4):3–14.
   Google Scholar
• Schaarschmidt M-L, Kromer C, Herr R, et al. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 2015;95(5):572–578.
   PubMed Web of Science ®Google Scholar
• Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319.
   PubMed Web of Science ®Google Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(3):61–67.
   PubMedGoogle Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–613.
   PubMed Web of Science ®Google Scholar
• Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl. 4):9–14.
   PubMed Web of Science ®Google Scholar
• Thorneloe RJ, Bundy C, Griffiths CEM, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.
   PubMed Web of Science ®Google Scholar
• Eicher L, Knop M, Aszodi N, et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253–2263.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a National Panel Study of Chronic Disease. Health Qual Life Outcomes. 2004;2:12.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(2):10–16.
   PubMedGoogle Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729–736.
   PubMed Web of Science ®Google Scholar
• van Cranenburgh OD, Korte JD, Sprangers MAG, et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398–405.
   PubMed Web of Science ®Google Scholar
• Hoelker S, Ninosu N, Buettner S, et al. Patient preferences for topical psoriasis treatments: a discrete choice experiment. J Dermatolog Treat. 2022;33(5):2595–2604.
   PubMed Web of Science ®Google Scholar
• Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003;9(1):2.
   PubMedGoogle Scholar
• Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383–392.
   PubMed Web of Science ®Google Scholar
• Bakshi H, Nagpal M, Singh M, et al. Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf. 2020;15(2):82–104.
   PubMed Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 2: treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges. 2021;19(7):1092–1115.
   Web of Science ®Google Scholar
• Feldman SR. Approaching psoriasis differently: patient–physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9(8):908–911.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995;34(10):700–703.
   PubMed Web of Science ®Google Scholar
• Maul J-T, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–708.
   PubMed Web of Science ®Google Scholar
• Iversen L, Jakobsen HB. Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol Ther. 2016;6(2):273–285.
   PubMed Web of Science ®Google Scholar
• Morgan MA, Small BJ, Donovan KA, et al. Cancer patients with pain: the spouse/partner relationship and quality of life. Cancer Nurs. 2011;34(1):13–23.
   PubMed Web of Science ®Google Scholar
• Hjortsberg C, Bergman A, Bjarnason A, et al. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm Venereol. 2011;91(4):409–414.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337(8735):193–196.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12(1):92–98.
   PubMed Web of Science ®Google Scholar
• Yan R, Jiang S, Wu Y, et al. Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: a systematic review. Indian J Dermatol Venereol Leprol. 2016;82(2):135–144.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Kircik L, Lacour J-P, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269–1277.
   PubMed Web of Science ®Google Scholar
• Hoegsberg T, Iversen L, Lange MM, et al. Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. J Dermatolog Treat. 2021;32(8):916–921.
   PubMed Web of Science ®Google Scholar
• Painsi C, Patscheider M, Inzinger M, et al. Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey. J Dtsch Dermatol Ges. 2015;13(11):1156–1163.
   PubMed Web of Science ®Google Scholar
• Lé AM, Torres T. New topical therapies for psoriasis. Am J Clin Dermatol. 2022;23(1):13–24.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Tapinarof cream 1%: first approval. Drugs. 2022;82(11):1221–1228.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073–1084.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen KE. The significance of the Lattice-System Physician’s Global Assessment as a research tool for measuring mild-to-moderate psoriasis. J Am Acad Dermatol. 2022;86(3):e111–e112.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Feldman SR, Tiedemann SN, et al. Psoriasis patient preferences for topical drugs: a systematic review. J Dermatolog Treat. 2021;32(5):478–483.
   PubMed Web of Science ®Google Scholar